DUPIXENT simultaneously improved asthma control while reducing or eliminating steroids1,2

No biomarker requirement (VENTURE, ITT population): Reduced or eliminated OCS dose and reduced severe exacerbation rates and improved lung function (secondary endpoints) at Week 241,2,d-f

a At Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 68% with placebo + SOC (n=107).2

b At Week 24 with DUPIXENT 300 mg + SOC (n=103) vs placebo + SOC (n=107) (0.65 vs 1.60; rate ratio: 0.41 [95% CI: 0.26, 0.63]).1

c At Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 10 mL with placebo + SOC (n=107) (LSM difference: 220 mL [95% CI: 90, 340 mL]).2

  • Effects on lung function and on oral steroid and exacerbation reduction were similar irrespective of baseline blood eosinophil levels. Subjects with baseline blood eosinophil levels up to 1500 cells/μL were included1
  • 70% significant reduction in OCS dose (median 100%) from baseline at Week 24 with DUPIXENT 300 mg + SOC (n=103) (95% CI: 60%, 80%) vs 42% (median 50%) with placebo + SOC (n=107) (primary endpoint)1

d ITT population was unrestricted by minimum baseline EOS or other type 2 biomarkers (eg, FeNO or IgE).2

e The baseline mean OCS dose was 12 mg in the placebo group and 11 mg in the group receiving DUPIXENT.1

f Asthma exacerbation was defined as a temporary increase in OCS dose for at least 3 days.1

DUPIXENT eliminated or reduced OCS dose for up to ~3 years5

79%

of patients from venture eliminated their ocs dose

A gradual increase in the number of patients eliminating their OCS dose was observed from 53.3% at Week 0 (n=48) to 59.6% at Week 48 (n=34)
to 78.9% at Week 96 (n=15) in the DUPIXENT/DUPIXENT group (secondary endpoint)5

  • 88% reduction in OCS dose in the DUPIXENT/DUPIXENT group of patients rolled over from the VENTURE study at
    Week 96 (n=19)5

There are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attrition of nonresponders.

Results are descriptive.

OCS reduction was at investigators’ discretion.5

VIEW THE FULL LONG-TERM EFFICACY AND SAFETY DATA

PATIENTS REQUIRING MAINTENANCE OCS MAY ALSO HAVE UNDERLYING TYPE 2 INFLAMMATION3

However, biomarkers of type 2
inflammation are often suppressed
by OCS.3

NO BIOMARKER TESTING REQUIRED
for 99% of OCS-dependent asthma patients who are commercially insured.4